Gapping up
In reaction to earnings/guidance:
- SIX +9.2%, AXSM +5.8%, DK +5.1%, BNTX +4.8%, HNI +3.5%, VTRS +2.6%, ACRS +2%, BRK.B +1.6%, ENR +1.4%
Other news:
- PACW +37% (reduces quarterly dividends)
- BAK +26.8% (provides update to media reports regarding proposal to purchase Braskem's control)
- SPB +8% (Spectrum Brands and the DOJ reach a settlement regarding the HHI Acquisition)
- MNK +4.9% (presents clinical data for TERLIVAZ for injection in adults with hepatorenal syndrome at Digestive Disease Week 2023)
- EL +3.4% (Nelson Peltz mulling shakeup at Estee Lauder)
- KDNY +2.9% (Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress)
- CNO +2.6% (approves additional $500 mln for share repurchases bringing the total to ~$672 mln; raises dividend 7% to $0.15/share)
- MCRB +2.5% (Seres Therapeutics and Nestlé Health Science announce the presentation of data from the Phase 3 open-label ECOSPOR IV study evaluating VOWST)
- LXU +2.2% (authorized a stock repurchase program)
- KALV +2% (presents data at 13th C1-inhibitor deficiency & angioedema workshop)
- SGHT +1.7% (announces 12-month Results from the First Minimally Invasive Glaucoma Surgery)
- BGNE +1.1% (receives new approvals for BRUKINSA in China)
- ING +1% (positive Barron's article)
Analyst comments:
- AY +4.7% (upgraded to Outperform from Sector Perform at National Bank Financial)
- SMG +3.7% (upgraded to Overweight from Neutral at JP Morgan)
- AAL +3.2% (upgraded to Overweight from Neutral at JP Morgan)
- COLD +1.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)